

# Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

## Supplementary Material

**Table S1. Baseline characteristics of population excluded because of missing information**

	Control group (n = 739)	Tocilizumab (n = 79)	p
<b>Age, median (IQR)</b>	n=739	69 (54 – 81)	n=79
			67 (58 – 75) 0.312
<b>Gender, n (%)</b>			
Male	n=407	407 (55)	n=55
Female	n=332	332 (45)	n=24
			55 (70) 24 (30) 0.013
<b>Past medical history, n (%)</b>			
Hypertension	n=739	133 (18)	n=79
Diabetes	n=739	199 (27)	n=79
Congestive heart failure	n=739	31 (4)	n=79
Coronary artery disease	n=739	50 (7)	n=79
Chronic kidney disease	n=739	31 (4)	n=79
Lung disease	n=739	55 (7)	n=79
			20 (25) 25 (32) 4 (5) 6 (8) 1 (1) 3 (4) 0.120 0.391 0.727 0.794 0.202 0.225
<b>Vital signs at admission</b>			
Heart rate (bpm), median (IQR)	n=683	80 (71 – 90)	n=68
Systolic blood pressure (mmHg), median (IQR)	n=506	126 (112 – 140)	n=45
Temperature (°C), median (IQR)	n=715	36.4 (36 – 37)	n=71
Peripheral oxygen saturation (%), median (IQR)	n=378	95 (93 – 97)	n=14
Needing supplemental oxygen	n=734	190 (26)	n=79
			82 (72 – 93) 120 (110 – 133) 36.6 (36.1 – 37.1) 93 (85 – 95) 18 (23) 0.563 0.049 0.099 0.002 0.548

<b>Baseline laboratory</b>					
Absolute lymphocyte count (cells/uL), median (IQR)	n=582	110 (790 - 1560)	n=71	890 (700 - 1250)	0.003
Absolute neutrophil count (cells/uL), median (IQR)	n=582	4550 (3060 - 6800)	n=71	6210 (3720 - 10360)	<0.001
LDH (U/L), median (IQR)	n=524	482 (388 - 630)	n=69	628 (489 - 942)	<0.001
ALT (U/L), median (IQR)	n=500	24 (16 - 39)	n=71	30 (20 - 41)	0.037
Urea (mg/dL), median (IQR)	n=519	35 (27 - 51)	n=68	38 (25 - 50)	0.522
C-reactive protein (mg/L), median (IQR)	n=551	54 (18-114)	n=71	120 (40-208)	<0.001
D-dimer (ng/mL), median (IQR)	n=385	636 (370 - 1519)	n=67	784 (525 - 1754)	0.038
Interleukin 6 (pg/mL), median (IQR)	n=6	41 (18 - 193)	n=10	34 (14 - 820)	0.983
<b>Outcome</b>					
Non-ICU length of stay (days), median (IQR)	n=739	7 (4 - 9)	n=79	14 (10 - 19)	<0.001
ICU admission, n (%)	n=739	38 (5)	n=79	28 (35)	<0.001
ICU length of stay (days), median (IQR)	n=38	2 (1 - 3)	n=28	6 (2 - 11)	0.006
Mortality, n (%)	n=739	123 (17)	n=79	28 (35)	<0.001
ICU or mortality, n (%)	n=739	123 (17)	n=79	30 (38)	<0.001

Abbreviations: ALT, alanine aminotransferase; ICU, intensive care unit; IQR, interquartile range; LDH, lactate dehydrogenase.

**Table S2. Adjusted hazard ratios for tocilizumab use in marginal structural models.**

	C-reactive protein >150 mg/dL							C-reactive protein ≤ 150 mg/dL						
	Mortality				ICU or mortality			Mortality				ICU or mortality		
	No.	aHR	95% CI	p	aHR	95% CI	p	No.	aHR	95% CI	p	aHR	95% CI	p
All	286	0.34	0.16, 0.72	0.005	0.39	0.19, 0.80	0.011	943	1.21	0.65, 2.23	0.552	1.41	0.77, 2.58	0.264
Lymphocyte count < 1000 cells/uL	187	0.24	0.10, 0.57	0.001	0.24	0.10, 0.57	0.001	397	1.20	0.61, 2.37	0.591	1.37	0.69, 2.71	0.361
D-dimer > 1000 ng/mL	147	0.23	0.09, 0.61	0.003	0.23	0.09, 0.61	0.003	282	1.29	0.55, 3.03	0.555	1.35	0.58, 3.13	0.489
Receiving corticosteroids	176	0.39	0.17, 0.90	0.028	0.44	0.20, 0.98	0.046	406	0.86	0.44, 1.65	0.645	1.00	0.43, 1.88	0.995
Receiving hydroxychloroquine	270	0.32	0.13, 0.79	0.015	0.38	0.16, 0.91	0.030	864	1.35	0.69, 2.63	0.373	1.59	0.83, 3.05	0.163
Receiving azithromycin	212	0.39	0.12, 1.22	0.105	0.44	0.16, 1.20	0.108	600	1.07	0.42, 2.70	0.894	1.31	0.54, 3.17	0.550
Receiving lopinavir/ritonavir	199	0.26	0.77, 0.88	0.030	0.34	0.11, 1.13	0.079	554	1.40	0.56, 3.54	0.472	1.75	0.72, 4.27	0.219

Table shows adjusted hazard ratios for tocilizumab versus non-tocilizumab (reference category).

Models adjusted for sex, age, comorbidities (hypertension, diabetes, ischemic heart disease, chronic kidney disease, congestive heart failure, lung disease), need for oxygen therapy at baseline, oxygen blood saturation and time-varying parameters of severity (blood pressure, heart rate, total lymphocyte and neutrophil count, LDH, ALT, urea, D-dimer, and C reactive protein).

Abbreviations: aHR, adjusted hazard ratio; ALT, alanine aminotransferase, CI, confidence interval; LDH, lactate dehydrogenase; No, number of individuals.